Bedfont Scientific’s NObreath FeNO monitor has been cleared by the US Food and Drug Administration (FDA).
Launched in September, the NObreath FeNO monitor is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath.
Offering a quick and non-invasive process, the NObreath FeNO measures FeNO through breath analysis.
Nitric oxide is often found to be increased in inflammatory conditions such as asthma.
Jason Smith, Managing Director at Bedfont, said, “NObreath has been available outside the US for over 12 years now, we have been working towards FDA clearance for quite some time and we are over the moon to have received it.
“We are one step closer to achieving our purpose to make FeNO monitoring lower cost and therefore more accessible globally. According to the Centre for Disease Control (CDC), around 25 million Americans suffering from asthma; that’s a potential 25 million people that the NObreath® can help through FeNO monitoring.”